HIGHLIGHTS
- who: Huan Wang from the (UNIVERSITY) have published the paper: Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis, in the Journal: (JOURNAL)
- what: The POTHER trial, the first phase II prospective trial aiming to assess the effectiveness of cetuximab plus triplet chemotherapy in colorectal liver metastasis (CLM), achieved an ORR and secondary R0 resection rate (R0RR) of 79.1% and 60%, respectively, with tolerable toxicity . Since one of the important objectives of anti-EGFR plus triplet chemotherapy treatment was to enhance the R0RR . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.